NASDAQ:VERU

VERU ALERT: Bragar Eagel & Squire, P.C. is Investigating Veru Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on: 
Friday, December 15, 2023
Class Action Lawsuit, Professional Services, Legal, NDA, Breast, Acute respiratory distress syndrome, Safety, Telephone, Complaint, Mortality, Patient, Fast track (FDA), Infection, FDA, Prostate cancer, Prostate Cancer Foundation, Jeanne Eagels, Aerospace, COVID-19, Standard of care, Trial of the century, Death, P.C, Form 10-Q, Fast Track, News, Cryptocurrency, Pharmaceutical industry, Tiberius Claudius Verus

Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.

Key Points: 
  • Our investigation concerns whether the board of directors of Veru have breached their fiduciary duties to the company.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.
  • At the time, there was no authorized or approved treatment for hospitalized patients with severe COVID-19 infections.

VERU INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Veru Inc. - VERU

Retrieved on: 
Monday, October 16, 2023
Class Action Lawsuit, Professional Services, Legal, COVID-19, Food, KSF, EUA, COVID, Emergency Use Authorization, FDA, Regulation of tobacco by the U.S. Food and Drug Administration, Pharmaceutical industry, Verus Pharmaceuticals

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Veru Inc. (NasdaqCM: VERU).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into Veru Inc. (NasdaqCM: VERU).
  • Then, on March 2, 2023, the Company announced that the FDA formally declined its EUA request.
  • KSF’s investigation is focusing on whether Veru’s officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nation’s premier boutique securities litigation law firms.

Lifshitz Law PLLC Announces Investigations of Generac Holdings Inc. (NYSE: GNRC), Veru Inc. (NASDAQ: VERU), The Gap, Inc. (NYSE: GPS), and NeoGenomics, Inc. (NASDAQ: NEO)

Retrieved on: 
Friday, March 17, 2023
EUA, Old Navy, NeoGenomics, Generac, Telephone, Marie Cassidy, Cancer, Emergency Use Authorization, Advertising, FDA, Hewlett, Safety, Mail, Pharmaceutical industry, Verus Pharmaceuticals

If you are a Generac investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.

Key Points: 
  • If you are a Generac investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • If you are a Veru investor, and would like additional information about our investigation, please complete the Information Request Form or contact Joshua Lifshitz, Esq.
  • The law firm responsible for this advertisement is Lifshitz Law PLLC, 1190 Broadway, Hewlett, New York 11557, Tel: (516)493-9780.
  • Prior results do not guarantee or predict a similar outcome with respect to any future matter.

Gainey McKenna & Egleston Investigates Potential Claims On Behalf of Investors of Veru, Inc. (VERU)

Retrieved on: 
Monday, March 13, 2023
EUA, COVID-19, FDA, Mortality, Patient, Pharmaceutical industry

VERU’s filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.

Key Points: 
  • VERU’s filings therefore concealed the true risks faced by the Company in gaining approval for its EUA request.
  • Veru conducted a randomized, double-blind Phase 3 trial of sabizabulin’s effectiveness in treating hospitalized adults with moderate to severe COVID-19 at high risk for ARDS.
  • The Phase 3 study sought to enroll 210 patients and evaluate mortality after 60 days of treatment.
  • of Gainey McKenna & Egleston at (212) 983-1300, or via e-mail at [email protected] or [email protected] .

Investigation Alert GRNC, VERU, GPS, UIS: Johnson Fistel, LLP Encourages Long-Term Investors to Contact the Firm; Should Management be Held Accountable for Investors’ Losses?

Retrieved on: 
Friday, February 24, 2023
Safety, UIS, Generac, NYSE, LLP, GPS, Gap, FDA, Bank statement, Unisys, The Gap, EUA, Old Navy, Navy, Insurance, Video game, Pharmaceutical industry

Johnson Fistel, LLP is investigating potential claims on behalf Generac Holdings Inc. (NYSE: GNRC) against certain of its officers and directors.

Key Points: 
  • Johnson Fistel, LLP is investigating potential claims on behalf Generac Holdings Inc. (NYSE: GNRC) against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Veru Inc. (NASDAQ: VERU) against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of The Gap, Inc. (NYSE: GPS) against certain of its officers and directors.
  • Johnson Fistel, LLP is investigating potential claims on behalf of Unisys Corporation (NYSE: UIS) against certain of its officers and directors.

Final Deadline Alert: Bronstein, Gewirtz & Grossman, LLC Reminds Veru Inc. (VERU) Investors of Class Action and to Actively Participate

Retrieved on: 
Monday, February 6, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Court, Complaint, NDA, Person, EUA, Verus Pharmaceuticals

Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/veru .

Key Points: 
  • Such investors are encouraged to join this case by visiting the firm’s site: www.bgandg.com/veru .
  • This class action seeks to recover damages against Defendants for alleged violations of the federal securities laws.
  • or his Law Clerk and Client Relations Manager, Yael Nathanson of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484.
  • Bronstein, Gewirtz & Grossman, LLC represents investors in securities fraud class actions and shareholder derivative suits.

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Veru Inc. (VERU)

Retrieved on: 
Friday, February 3, 2023
Class Action Lawsuit, Professional Services, Legal, FDA, Court, Law, Suite, Verus Pharmaceuticals, COVID-19, News, EUA, Cryptocurrency, Pharmaceutical industry

The Law Offices of Frank R. Cruz reminds investors of the upcoming February 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU ) common stock between May 11, 2022 and November 9, 2022, inclusive (the “Class Period”).

Key Points: 
  • The Law Offices of Frank R. Cruz reminds investors of the upcoming February 6, 2023 deadline to file a lead plaintiff motion in the class action filed on behalf of investors who acquired Veru Inc. (“Veru” or the “Company”) (NASDAQ: VERU ) common stock between May 11, 2022 and November 9, 2022, inclusive (the “Class Period”).
  • If you purchased or otherwise acquired Veru common stock during the Class Period, you may move the Court no later than February 6, 2023 to request appointment as lead plaintiff in this putative class action lawsuit.
  • To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
  • This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.

VERU DEADLINE ALERT: Bragar Eagel & Squire, P.C. Reminds Investors that a Class Action Lawsuit Has Been Filed Against Veru Inc. and Encourages Investors to Contact the Firm

Retrieved on: 
Thursday, February 2, 2023
Class Action Lawsuit, Professional Services, Legal, NDA, Acute respiratory distress syndrome, Standard of care, Trial of the century, Form 10-Q, Breast, Tiberius Claudius Verus, Safety, P.C, Patient, Telephone, Jeanne Eagels, News, Fast track (FDA), Prostate cancer, Mortality, Aerospace, Person, Death, Prostate Cancer Foundation, FDA, Court, Steiner, COVID-19, Fast Track, Infection, EUA, Pharmaceutical industry

Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.

Key Points: 
  • Investors have until February 3, 2023 to apply to the Court to be appointed as lead plaintiff in the lawsuit.
  • Veru is primarily an oncology-based biopharmaceutical company that develops drugs for the management of breast and prostate cancers.
  • Veru also develops medicines for COVID-19 and other diseases related to viral and acute respiratory distress syndrome (“ARDS”), and has two FDA-approved products for sexual health.
  • Veru had originally developed sabizabulin with the intention of using it as a treatment for prostate cancer.

DEADLINE ALERT for VERU and NEO: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

Retrieved on: 
Monday, February 6, 2023
NeoGenomics, Abuse, Complaint, NGS, Suite, Defendant, Marcus Annius Verus Caesar, EUA, Investment, Fraud, Law, Mail, Holding company

LOS ANGELES, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.

Key Points: 
  • LOS ANGELES, Feb. 06, 2023 (GLOBE NEWSWIRE) -- The Law Offices of Frank R. Cruz reminds investors that class action lawsuits have been filed on behalf of shareholders of the following publicly-traded companies.
  • Investors have until the deadlines listed below to file a lead plaintiff motion.
  • Investors suffering losses on their investments are encouraged to contact The Law Offices of Frank R. Cruz to discuss their legal rights in these class actions at 310-914-5007 or by email to [email protected] .
  • The Law Offices of Frank R. Cruz, Los Angeles

SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Veru Inc. - VERU

Retrieved on: 
Saturday, February 4, 2023
Food, COVID-19, Acute respiratory distress syndrome, Advisory Committee, Patient, Defense Department Advisory Committee on Women in the Services, News, Pharmaceutical industry

NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).

Key Points: 
  • NEW YORK, Feb. 04, 2023 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Veru, Inc. (“Veru” or the “Company”) (NASDAQ: VERU).
  • Such investors are advised to contact Robert S. Willoughby at [email protected] or 888-476-6529, ext.
  • The investigation concerns whether Veru and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.
  • Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, the Pomerantz Firm pioneered the field of securities class actions.